drugset

drugset / Trial / NCT05563389

Statin Impact on Hepatic Decompensation

NCT05563389 ↗

Phase 2/3 Completed 100 enrolled Tanta University

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study aims to evaluate the impact of statin on hepatic decompensation.

Timeline

Start: 2022-06-15
Primary completion: 2023-02-25
Completion: 2023-02-25

Publications

Glal KAM, El-Haggar SM, Abdel-Salam SM, Mostafa TM. Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial. Sci Rep. 2026 Mar 21;16(1):9669. doi: 10.1038/s41598-026-41326-4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Atorvastatin	Small molecule	20 mg	—

Indications

No indication recorded.